BXRX - Baudax Bio Inc Stock Price, Fair Value and News

0.01USD0.00 (0.00%)Delayed

Market Summary

USD0.010.00

Delayed

0.00%

BXRX Stock Price

View Fullscreen

BXRX RSI Chart

BXRX Valuation

Market Cap

435.9K

Price/Earnings (Trailing)

-0.12

Price/Sales (Trailing)

1.03

Price/Free Cashflow

-0.1

BXRX Price/Sales (Trailing)

BXRX Profitability

Operating Margin

-452.11%

Return on Equity

-79.13%

Return on Assets

-34.75%

Free Cashflow Yield

-996.64%

BXRX Fundamentals

BXRX Revenue

Revenue (TTM)

1.3M

BXRX Earnings

Earnings (TTM)

-7.2M

Earnings Growth (Yr)

93.38%

Earnings Growth (Qtr)

73.78%

Breaking Down BXRX Revenue

Last 90 days

-50%

Trailing 12 Months

-98.7%

How does BXRX drawdown profile look like?

BXRX Financial Health

Current Ratio

0.07

BXRX Investor Care

Shares Dilution (1Y)

8616.98%

Diluted EPS (TTM)

88.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	1.3M	1.4M	1.4M	1.3M
2021	639.8K	786.5K	933.3K	1.1M
2020	0	0	0	493.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Baudax Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 15, 2022	henwood geraldine	bought	3,057	2.5476	1,200	president and ceo
Jun 15, 2022	baskies arnold m	acquired	-	-	39,473	-
Jun 15, 2022	weisman wayne	acquired	-	-	39,473	-
Jun 15, 2022	dilmore jillian	acquired	-	-	15,467	corporate controller/secretary
Jun 15, 2022	ashton william	acquired	-	-	39,473	-
Jun 15, 2022	churchill winston j	acquired	-	-	39,473	-
Jun 15, 2022	drechsler andrew t	acquired	-	-	39,473	-
Jun 15, 2022	henwood geraldine	acquired	-	-	39,473	president and ceo
Dec 15, 2021	henwood geraldine	sold (taxes)	-5,777	0.31	-18,636	president and ceo
Dec 05, 2021	henwood geraldine	sold (taxes)	-3,204	0.35	-9,155	president and ceo

Which funds bought or sold BXRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	SITTNER & NELSON, LLC	unchanged	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	sold off	-100	-	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-16,000	-	-%

Are Funds Buying or Selling BXRX?

Are funds buying BXRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BXRX

No. of Funds

Unveiling Baudax Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	black horse capital lp	0%	0	SC 13G/A
Feb 06, 2024	intracoastal capital, llc	1.8%	814,383	SC 13G/A
Jul 10, 2023	black horse capital lp	0.5%	40,000	SC 13G/A
Feb 14, 2023	armistice capital, llc	4.99%	1,165,709	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	5.1%	27,092	SC 13G/A
Sep 06, 2022	intracoastal capital, llc	6.5%	1,091,652	SC 13G
May 27, 2022	intracoastal capital, llc	4.99%	423,782	SC 13G
Feb 15, 2022	armistice capital, llc	9.99%	8,869,545	SC 13G/A
Jan 06, 2022	intracoastal capital, llc	2.1%	1,870,469	SC 13G
Feb 16, 2021	corsair capital management, l.p.	1%	34,160	SC 13G

Recent SEC filings of Baudax Bio Inc

View All Filings

Date Filed	Form Type	Document
Feb 28, 2024	8-K	Current Report
Feb 15, 2024	25-NSE	25-NSE
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Baudax Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Baudax Bio Inc News

Latest updates

Baudax Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-100.0%	-	30,000	169,750	309,500	238,000	300,000	422,000	400,000	281,000	201,000	198,000	133,000	68,000	349,000
Cost Of Revenue	-	-	-	-	4,792,000	1,208,000	361,000	648,000	576,000	462,000	586,000	821,000	-	540,000	650,000
Costs and Expenses	-74.8%	1,776,000	7,045,000	4,688,000	2,932,000	3,575,000	3,776,000	7,623,000	-24,182,000	16,661,000	16,517,000	16,520,000	4,363,000	12,194,000	30,581,000
S&GA Expenses	61.4%	3,639,000	2,254,000	1,771,000	1,928,000	2,953,000	2,898,000	6,934,000	-10,845,000	11,074,000	10,608,000	12,088,000	10,309,000	13,763,000	11,217,000
R&D Expenses	6.9%	1,901,000	1,779,000	2,917,000	1,004,500	622,000	879,000	694,000	26,000	658,000	857,000	1,108,000	3,198,000	1,469,000	1,350,000
EBITDA Margin	-	-	-	-	-	-	-12.32	-13.24	-15.95	-	-	-108	-151	-	-
EBT Margin	-	-	-	-	-	-	-14.09	-15.16	-18.30	-	-	-110	-154	-39.04	-23.32
Net Income	73.8%	-1,934,000	-7,375,000	11,404,000	-9,248,500	-29,207,000	-7,531,000	-12,809,000	29,434,000	-16,962,000	-15,329,000	-16,912,000	-17,042,000	11,685,000	-30,445,000
Net Income Margin	79.2%	-5.63	-27.12	-27.24	-46.31	-14.79	-5.61	-12.01	-18.30	-70.98	-47.80	-82.40	-154	-	-
Free Cashflow	29.5%	-2,390,000	-3,392,000	-3,958,000	-3,354,000	-3,071,000	-4,234,000	-5,792,000	14,208,000	-12,568,000	-10,054,000	-14,078,000	-14,964,000	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																		(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-3.4%	20,583	21,316	7,065	10,032	17,510	40,834	48,813	53,277	61,499	73,808	74,986	68,733	61,467	75,487	74,154	54,213	35,985	35,023
Current Assets	-28.1%	1,338	1,860	4,108	6,347	11,269	12,479	19,716	23,494	31,138	43,281	43,690	36,717	28,955	42,667	40,495	20,135	1,658	2,514
Cash Equivalents	-74.4%	363	1,416	3,803	5,259	5,647	5,210	11,527	15,891	14,772	25,412	30,690	30,342	24,608	39,410	38,284	17,740	-	-
Inventory	-	-	-	-	-	4,477	5,255	5,212	5,002	4,310	3,558	2,773	2,978	1,784	753	-	-	-	-
Net PPE	-2.9%	3,671	3,781	1.00	9.00	1,239	4,941	4,992	69.00	4,933	4,979	5,039	5,052	4,835	4,610	4,716	4,821	4,968	3,982
Goodwill	-4.8%	8,797	9,236	2,127	2,127	2,127	2,127	2,127	2,127	2,127	2,127	2,127	2,127	2,127	2,127	2,127	2,127	2,127	2,127
Liabilities	-5.1%	21,781	22,955	14,378	34,274	37,050	36,604	39,070	40,051	82,227	78,381	75,980	83,532	106,697	134,891	110,046	70,934	71,408	103,370
Current Liabilities	-6.9%	19,051	20,457	12,371	21,460	21,275	18,181	20,397	15,646	14,442	13,822	14,123	18,129	19,922	20,153	18,705	7,713	5,217	22,780
Long Term Debt	-	-	-	1,433	1,519	2,175	5,099	5,099	6,309	6,913	7,518	8,185	8,469	8,753	8,097	-	-	-	-
LT Debt, Current	-13.0%	4,228	4,861	6,000	5,600	5,911	3,611	3,611	2,222	1,389	555	1,196	683	171	598	-	-	-	-
LT Debt, Non Current	-	-	-	1,433	1,519	2,175	5,099	5,099	6,309	6,913	7,518	8,185	8,469	8,753	8,097	-	-	-	-
Shareholder's Equity	0%	9,040	9,040	172,161	166,646	157,483	4,229	9,743	13,226	140,771	139,964	128,218	97,521	49,864	47,375	40,450	19,405	-	-
Retained Earnings	-1.3%	-189,300	-186,875	-179,500	-190,904	-181,654	-152,429	-144,898	-132,089	-161,523	-144,561	-129,232	-112,320	-95,278	-106,963	-76,518	-36,220	-	-
Additional Paid-In Capital	1.6%	178,940	176,126	172,161	166,646	161,914	156,578	154,577	145,314	139,951	139,145	127,537	97,034	49,864	47,375	40,450	19,405	-	-
Shares Outstanding	74.7%	12,165	6,962	2,586	1,624	192	140	101	70.00	60.00	49.00	50.00	35.00	-	-	-	-	-	-
Float	-	-	-	-	-	-	6,800	-	-	-	62,700	-	-	-	70,800	-	-	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	29.7%	-2,370	-3,372	-3,938	-3,334	-3,091	-4,234	-5,772	14,335	-12,568	-10,051	-14,005	-14,632	-11,805	-11,307	-6,314	-7,940	-2,946	-24,696	-14,462	-	-
Share Based Compensation	27.8%	253	198	191	227	276	295	491	-537	925	903	2,304	1,910	2,489	2,309	2,633	1,209	1,052	1,675	1,527	-	-
Cashflow From Investing	-Infinity%	-21.00	-	-	-	-	20.00	-20.00	10,226	2,006	-4,655	-7,568	-332	-	-	-	314	-81.00	-1,356	-361	-	-
Cashflow From Financing	50.6%	1,381	917	3,208	3,395	4,525	1,402	9,059	11,611	-78.00	9,428	21,921	20,698	-2,690	12,433	26,858	25,366	3,027	26,052	14,823	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BXRX Income Statement

2023-09-30

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 1,901	$ 622	$ 6,597	$ 2,196
General and administrative	3,639	2,953	7,664	12,785
Change in fair value of warrants and derivatives	(3,587)	0	(717)	(7)
Change in contingent consideration valuation	(177)	0	(35)	0
Total operating expenses	1,776	3,575	13,509	14,974
Operating loss from continuing operations	(1,776)	(3,575)	(13,509)	(14,974)
Other expense:
Other expense, net	(115)	(512)	(3,069)	(1,652)
Net loss from continuing operations	(1,891)	(4,087)	(16,578)	(16,626)
Income (loss) on discontinued operation	(43)	(25,120)	18,673	(32,920)
Net income (loss)	$ (1,934)	$ (29,207)	$ 2,095	$ (49,546)
Per share information:
Net loss per share from continuing operations, basic	$ (0.29)	$ (13.81)	$ (3.36)	$ (86.53)
Net loss per share from continuing operations, diluted	(0.29)	(13.81)	(3.36)	(86.53)
Net income (loss) per share from discontinued operations, basic	(0.01)	(84.89)	3.69	(171.34)
Net income (loss) per share from discontinued operations, diluted	(0.01)	(84.89)	3.69	(171.34)
Net income (loss) per share, basic	(0.3)	(98.7)	0.33	(257.87)
Net income (loss) per share, diluted	$ (0.3)	$ (98.7)	$ 0.33	$ (257.87)
Weighted average common shares outstanding, basic	7,993,522	295,903	5,065,759	192,135
Weighted average common shares outstanding, diluted	7,993,522	295,903	5,065,759	192,135

BXRX Balance Sheet

2023-09-30

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 363	$ 5,259
Prepaid expenses and other current assets	975	303
Current assets of discontinued operation	0	785
Total current assets	1,338	6,347
Property and equipment, net	3,671	9
Right-of-use asset	2,877	854
Intangible asset	3,900	0
Goodwill	8,797	2,127
Non-current assets of discontinued operation	0	695
Total assets	20,583	10,032
Current liabilities:
Accounts payable	7,822	3,198
Accrued expenses and other current liabilities	3,652	2,133
Current portion of long-term debt, net	4,228	5,600
Current portion of operating lease liability	341	231
Contingent consideration	83	0
Convertible bond payable	1,000	0
Derivative instrument	1,659	0
Other current liabilities	266	0
Current liabilities of discontinued operation	0	10,298
Total current liabilities	19,051	21,460
Long-term portion, net	0	1,519
Long-term operating lease liability	2,528	585
Deferred Tax Liability	202	0
Other long-term liabilities	0	13
Non-current liabilities of discontinued operation	0	10,697
Total liabilities	21,781	34,274
Commitments and contingencies (Note 12)
Shareholders' (deficit) equity:
Preferred stock, $0.01 par value. Authorized, 10,000,000 shares; shares issued and outstanding, 36,267 at September 30, 2023 and 0 December 31, 2022	0	0
Common stock, $0.01 par value. Authorized, 190,000,000 shares; issued and outstanding, 12,164,753 shares at September 30, 2023 and 1,623,913 shares at December 31, 2022	122	16
Additional paid-in capital	178,940	166,646
Accumulated deficit	(189,300)	(190,904)
Total shareholders' deficit	(10,238)	(24,242)
Total liabilities, non-voting convertible preferred stock and shareholders' deficit	20,583	10,032
Series X Non-Voting Convertible Preferred Stock [Member]
Mezzanine equity:
Series X non-voting convertible preferred stock, $0.01 par value, Authorized, 27,090 shares; issued and outstanding 20,066 shares at September 30, 2023	$ 9,040	$ 0

About Baudax Bio Inc

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

CEO	Dr. Geraldine A. Henwood Ph.D.
WEBSITE	baudaxbio.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Baudax Bio Inc Frequently Asked Questions

What is the ticker symbol for Baudax Bio Inc? What does BXRX stand for in stocks?

BXRX is the stock ticker symbol of Baudax Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Baudax Bio Inc (BXRX)?

As of Thu May 02 2024, market cap of Baudax Bio Inc is 435.93 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BXRX stock?

You can check BXRX's fair value in chart for subscribers.

What is the fair value of BXRX stock?

You can check BXRX's fair value in chart for subscribers. The fair value of Baudax Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Baudax Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BXRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Baudax Bio Inc a good stock to buy?

The fair value guage provides a quick view whether BXRX is over valued or under valued. Whether Baudax Bio Inc is cheap or expensive depends on the assumptions which impact Baudax Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BXRX.

What is Baudax Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, BXRX's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 1.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BXRX PE ratio will change depending on the future growth rate expectations of investors.